Influenza M2 virus-like particles confer a broader range of cross protection to the strain-specific pre-existing immunity

Vaccine

Volumn 32, Issue 44, 2014, Pages 5824-5831

  Kim, Min Chul ^a,b   Lee, Yu Na ^a   Hwang, Hye Suk ^a   Lee, Young Tae ^a   Ko, Eun Ju ^a   Jung, Yu Jin ^a   Cho, Min Kyoung ^a   Kim, Yu Jin ^a   Lee, Jong Seok ^a   Ha, Suk Hoon ^c   Kang, Sang Moo ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

^b Animal Plant and Fisheries Quarantine and Inspection Agency   (South Korea)

^c Mogam Biotechnology Research Institute   (South Korea)

Author keywords

Cross protection; Influenza vaccine; M2e5 VLPs; Pre existing immunity

Indexed keywords

GAMMA INTERFERON; HEMAGGLUTINATION INHIBITING ANTIBODY; INFLUENZA VACCINE; M2E VIRUS LIKE PARTICLE VACCINE; PLACEBO; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS LIKE PARTICLE VACCINE; IMMUNOGLOBULIN G; M2 PROTEIN, INFLUENZA A VIRUS; MATRIX PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS PROTECTION; CYTOKINE PRODUCTION; DRUG EFFICACY; FEMALE; INFLUENZA M2 VIRUS; INFLUENZA VACCINATION; INFLUENZA VIRUS; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; SEASONAL VARIATION; VIRUS IMMUNITY; VIRUS LIKE AGENT; VIRUS STRAIN; ANIMAL; BAGG ALBINO MOUSE; BLOOD; HEMAGGLUTINATION INHIBITION TEST; IMMUNOLOGY; ORTHOMYXOVIRIDAE INFECTIONS; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, VIRAL; CROSS PROTECTION; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INTERFERON-GAMMA; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; T-LYMPHOCYTES; VACCINES, VIRUS-LIKE PARTICLE; VIRAL MATRIX PROTEINS;

EID: 84908073773     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.08.030     Document Type: Article

References (30)

1. Nicholson K.G., Tyrrell D.A., Harrison P., Potter C.W., Jennings R., Clark A., et al. Clinical studies of monovalent inactivated whole virus and subunit A/USSR/77 (H1N1) vaccine: serological responses and clinical reactions. J Biol Stand 1979, 7:123-136.
2. Stephenson I., Nicholson K.G., Gluck R., Mischler R., Newman R.W., Palache A.M., et al. Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial. Lancet 2003, 362:1959-1966.
3. Cox J.C., Coulter A.R. Adjuvants-a classification and review of their modes of action. Vaccine 1997, 15:248-256.
4. Stohr K. Preventing and treating influenza. BMJ 2003, 326:1223-1224.
5. Hancock K., Veguilla V., Lu X., Zhong W., Butler E.N., Sun H., et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009, 361:1945-1952.
6. Smith G.J., Vijaykrishna D., Bahl J., Lycett S.J., Worobey M., Pybus O.G., et al. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature 2009, 459:1122-1125.
7. Peiris M., Yuen K.Y., Leung C.W., Chan K.H., Ip P.L., Lai R.W., et al. Human infection with influenza H9N2. Lancet 1999, 354:916-917.
8. Fouchier R.A., Schneeberger P.M., Rozendaal F.W., Broekman J.M., Kemink S.A., Munster V., et al. Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc Natl Acad Sci U S A 2004, 101:1356-1361.
9. Wong S.S., Yuen K.Y. Avian influenza virus infections in humans. Chest 2006, 129:156-168.
10. Lin J., Zhang J., Dong X., Fang H., Chen J., Su N., et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 2006, 368:991-997.
11. Kim M.C., Song J.M., Kwon O.E., Lee Y.M., Compans Y.J.R.W., et al. Virus-like Particles Containing Multiple M2 Extracellular Domains Confer Improved Cross-protection against various subtypes of influenza virus. Mol Ther 2013, 21:485-492.
12. Kim M.C., Lee J.S., Kwon Y.M.O.E., Lee Y.J., Choi J.G., et al. Multiple heterologous M2 extracellular domains presented on virus-like particles confer broader and stronger M2 immunity than live influenza A virus infection. Antivir Res 2013, 99:328-335.
13. Song J.M., Hossain J., Yoo D.G., Lipatov A.S., Davis C.T., Quan F.S., et al. Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles. Virology 2010, 405:165-175.
14. Quan F.S., Compans R.W., Nguyen H.H., Kang S.M. Induction of heterosubtypic immunity to influenza virus by intranasal immunization. J Virol 2008, 82:1350-1359.
15. Grantham M.L., Stewart S.M., Lalime E.N., Pekosz A. Tyrosines in the influenza A virus M2 protein cytoplasmic tail are critical for production of infectious virus particles. J Virol 2010, 84:8765-8776.
16. Quan F.S., Yoo D.G., Song J.M., Clements J.D., Compans R.W., Kang S.M. Kinetics of immune responses to influenza virus-like particles and dose-dependence of protection with a single vaccination. J Virol 2009, 83:4489-4497.
17. Song J.M., Wang B.Z., Park K.M., Van Rooijen N., Quan F.S., Kim M.C., et al. Influenza virus-like particles containing M2 induce broadly cross protective immunity. PLoS One 2011, 6:e14538.
18. Wen H.S., Wang S.P. Mouse adaptation of the Asian influenza virus. J Infect Dis 1959, 105:9-17.
19. Song J.M., Van Rooijen N., Bozja J., Compans R.W., Kang S.M. Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus. Proc Natl Acad Sci U S A 2011, 108:757-761.
20. Bush R.M., Bender C.A., Subbarao K., Cox N.J., Fitch W.M. Predicting the evolution of human influenza A. Science 1999, 286:1921-1925.
21. Plotkin J.B., Dushoff J. Codon bias and frequency-dependent selection on the hemagglutinin epitopes of influenza A virus. Proc Natl Acad Sci U S A 2003, 100:7152-7157.
22. Lee Y.N., Kim M.C., Lee Y.T., Hwang H.S., Cho M.K., Lee J.S., et al. AS04-adjuvanted virus-like particles containing multiple M2 extracellular domains of influenza virus confer improved protection. Vaccine 2014, 32:4578-4585.
23. Huber V.C., Lynch J.M., Bucher D.J., Le J., Metzger D.W. Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J Immunol 2001, 166:7381-7388.
24. Huber V.C., McKeon R.M., Brackin M.N., Miller L.A., Keating R., Brown S.A., et al. Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin Vaccine Immunol 2006, 13:981-990.
25. Mozdzanowska K., Feng J., Eid M., Zharikova D., Gerhard W. Enhancement of neutralizing activity of influenza virus-specific antibodies by serum components. Virology 2006, 352:418-426.
26. Jayasekera J.P., Moseman E.A., Carroll M.C. Natural antibody and complement mediate neutralization of influenza virus in the absence of prior immunity. J Virol 2007, 81:3487-3494.
27. Kim M.C., Lee Y.N., Ko E.J., Lee J.S., Kwon Y.M., Hwang H.S., et al. Supplementation of influenza split vaccines with conserved M2 ectodomains overcomes strain-specificity and provides long-term cross protection. Mol Ther 2014, 22(7):1364-1374.
28. Moran T.M., Park H., Fernandez-Sesma A., Schulman J.L. Th2 responses to inactivated influenza virus can be converted to Th1 responses and facilitate recovery from heterosubtypic virus infection. J Infect Dis 1999, 180:579-585.
29. Stevens T.L., Bossie A., Sanders V.M., Fernandez-Botran R., Coffman R.L., Mosmann T.R., et al. Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature 1988, 334:255-258.
30. Vanderplasschen A., Markine-Goriaynoff N., Lomonte P., Suzuki M., Hiraoka N., Yeh J.C., et al. A multipotential beta-1,6-N-acetylglucosaminyl-transferase is encoded by bovine herpesvirus type 4. Proc Natl Acad Sci U S A 2000, 97:5756-5761.